Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Free Cash Flow: 2012-2024

Historic Free Cash Flow for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$11.9 million.

  • Theravance Biopharma's Free Cash Flow fell 24.89% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.5 million, marking a year-over-year increase of 2078.82%. This contributed to the annual value of -$11.9 million for FY2024, which is 59.75% up from last year.
  • Latest data reveals that Theravance Biopharma reported Free Cash Flow of -$11.9 million as of FY2024, which was up 59.75% from -$29.5 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Free Cash Flow registered a high of -$11.9 million during FY2024, and its lowest value of -$269.4 million during FY2020.
  • Over the past 3 years, Theravance Biopharma's median Free Cash Flow value was -$29.5 million (recorded in 2023), while the average stood at -$76.3 million.
  • Per our database at Business Quant, Theravance Biopharma's Free Cash Flow fell by 11.60% in 2020 and then surged by 84.28% in 2023.
  • Theravance Biopharma's Free Cash Flow (Yearly) stood at -$269.4 million in 2020, then rose by 11.20% to -$239.2 million in 2021, then climbed by 21.58% to -$187.6 million in 2022, then surged by 84.28% to -$29.5 million in 2023, then skyrocketed by 59.75% to -$11.9 million in 2024.